Trial of aflibercept for pancreatic cancer halted

09/14/2009 | Reuters

A late-stage trial on the use of aflibercept in combination with gemcitabine as first-line treatment of pancreatic cancer was discontinued because of disappointing results. The drugmakers said they will continue testing aflibercept's effectiveness against metastatic colorectal cancer, metastatic prostate cancer and nonsmall-cell lung cancer.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN